Amazon gets in on it, a pill more powerful than Ozempic, and some competition: Weight loss drugs roundup
Plus, Novo Nordisk's Wegovy could be covered by Medicare
2 / 10
Competition in the weight loss drug industry continued to heat up this week. Eli Lilly has partnered with Amazon to ensure Zepbound users have a steady and safe supply of the drug. Novo Nordisk could soon see Medicare cover Wegovy, and its already teasing a next-gen weight loss pill. And several other pharma companies including Regeneron, Roche, and Amgen are looking to enter the market.
Check out the slideshow above for that and more news about weight loss drugs.
3 / 10
Users with a prescription of Eli Lilly’s weight loss drug, Zepbound, will now be able to get the medication delivered straight to their homes via Amazon. Demand for popular weight loss drugs like Novo Nordisk’s Ozempic has been outpacing supply.
4 / 10
U.S. pharma giant Eli Lilly announced that it is partnering with Amazon to deliver its weight loss drug Zepbound straight to users’ doors. Here are all the GLP-1 medications that are currently approved by the FDA for weight loss and where they’re available online.
5 / 10
Medicare could soon cover the popular weight loss drug Wegovy, after federal regulators expanded the approved use of the drug to include reducing serious heart risks for adults who are obese or overweight. Wegovy belongs to the same class of drug as the diabetes medication Ozempic, which is known for its weight loss side effects.
6 / 10
Danish pharma giant Novo Nordisk teased promising early-stage trial results of its experimental weight loss pill amycretin, sending the company’s stock surging. The company told investors that a small trial of the pill found that it could be twice as effective as the company’s current blockbuster weight loss drug.
7 / 10
The race is intensifying among pharmaceutical companies aiming to disrupt the weight loss drug duopoly dominated by Novo Nordisk, known for making Ozempic and Wegovy, and Eli Lilly, the producer of Zepbound. Surging demand for these medications has transformed the two pharmaceutical developers into some world’s most valuable companies — and they could become the first $1 trillion pharma firms.
8 / 10
Novo Nordisk CEO Lars Fruergaard Jørgensen said the company’s experimental weight loss pill, Amycretin, “could develop into a best-in-class medicine.” His comments on CNBC fter the company’s stock surged following the announcement of promising results for the drug. That sent Novo Nordisk’s market cap past Tesla’s and made it the 12th-most valuable company in the world.
9 / 10
After Novo Nordisk’s blockbuster weight loss drug Wegovy made its debut in Asia by launching in Japan last month, the pharma company says it now expects the drug to be approved in China this year.
10 / 10
The popular weight-loss drug Wegovy, which has helped millions of Americans shed pounds, can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, federal regulators said.